Alseres Pharmaceuticals (OTCMKTS:ALSE) and Korro Bio (NASDAQ:KRRO) Financial Contrast

Korro Bio (NASDAQ:KRRO) and Alseres Pharmaceuticals (OTCMKTS:ALSE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership.

Profitability

This table compares Korro Bio and Alseres Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,199.53%	-68.87%	-45.91%
Alseres Pharmaceuticals	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Korro Bio and Alseres Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1	8	1	0	2.00
Alseres Pharmaceuticals	0	0	0	0	0.00

Korro Bio presently has a consensus target price of $76.00, suggesting a potential upside of 862.63%. Given Korro Bio’s stronger consensus rating and higher probable upside, equities analysts plainly believe Korro Bio is more favorable than Alseres Pharmaceuticals.

Earnings & Valuation

This table compares Korro Bio and Alseres Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$2.27 million	32.76	-$83.58 million	($9.41)	-0.84
Alseres Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Alseres Pharmaceuticals has lower revenue, but higher earnings than Korro Bio.

Insider and Institutional Ownership

13.2% of Korro Bio shares are owned by institutional investors. 4.6% of Korro Bio shares are owned by insiders. Comparatively, 8.9% of Alseres Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Korro Bio beats Alseres Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Korro Bio

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

About Alseres Pharmaceuticals

Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson’s disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.